{"hands_on_practices": [{"introduction": "Effective clinical practice hinges on accurately interpreting diagnostic tests. This exercise demonstrates how to formally update your clinical suspicion using Bayes' theorem, a cornerstone of evidence-based medicine. By calculating the post-test probability of sporotrichosis after a positive PCR result [@problem_id:4492682], you will practice quantifying diagnostic certainty, a crucial skill for deciding whether to initiate treatment or seek further confirmation.", "problem": "A clinician in dermatology and venereology evaluates a patient with suspected sporotrichosis. Before testing, the clinician estimates the pretest probability of sporotrichosis to be $0.20$. The patient undergoes a polymerase chain reaction (PCR) assay for Sporothrix species, which has sensitivity $0.90$ and specificity $0.98$. Using Bayes’ theorem and the core definitions of sensitivity and specificity as conditional probabilities, derive from first principles an expression for the post-test probability of sporotrichosis given a positive PCR result, and compute its numerical value. Express the final probability as a decimal without a percent sign and round your answer to four significant figures. Then, based on your computed result, provide a brief interpretation for clinical decision-making in suspected sporotrichosis.", "solution": "The problem requires the derivation and calculation of the post-test probability of a disease (sporotrichosis) given a positive test result, based on the provided pretest probability, test sensitivity, and specificity. This is a direct application of Bayes' theorem in a clinical diagnostic context. We will first formalize the problem using standard probability notation, derive the required expression from fundamental principles, and then compute the numerical value.\n\nLet $D$ be the event that the patient has sporotrichosis.\nLet $D^c$ be the event that the patient does not have sporotrichosis.\nLet $T^+$ be the event that the polymerase chain reaction (PCR) assay result is positive.\nLet $T^-$ be the event that the PCR assay result is negative.\n\nFrom the problem statement, we are given the following probabilities:\nThe pretest probability of sporotrichosis is the prior probability of the disease, $P(D)$.\n$$P(D) = 0.20$$\nThe sensitivity of the PCR assay is the probability of a positive test result given that the patient has the disease, $P(T^+ | D)$.\n$$P(T^+ | D) = 0.90$$\nThe specificity of the PCR assay is the probability of a negative test result given that the patient does not have the disease, $P(T^- | D^c)$.\n$$P(T^- | D^c) = 0.98$$\n\nOur objective is to derive an expression for and compute the numerical value of the post-test probability of sporotrichosis given a positive PCR result. This corresponds to the conditional probability $P(D | T^+)$.\n\nBy the definition of conditional probability, we have:\n$$P(D | T^+) = \\frac{P(D \\cap T^+)}{P(T^+)}$$\n\nThe numerator, $P(D \\cap T^+)$, is the joint probability of having the disease and testing positive. It can be expressed using the definition of conditional probability as:\n$$P(D \\cap T^+) = P(T^+ | D) P(D)$$\nThis expression contains two of our given values: the sensitivity and the pretest probability.\n\nThe denominator, $P(T^+)$, is the total probability of obtaining a positive test result. We can expand this term using the law of total probability, by conditioning on whether the patient has the disease ($D$) or not ($D^c$). These two events form a partition of the sample space.\n$$P(T^+) = P(T^+ \\cap D) + P(T^+ \\cap D^c)$$\nUsing the definition of conditional probability for each term, we get:\n$$P(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)$$\n\nThis expansion introduces two new terms we need to determine: $P(D^c)$ and $P(T^+ | D^c)$.\nThe probability of not having the disease, $P(D^c)$, is the complement of having the disease, $P(D)$:\n$$P(D^c) = 1 - P(D) = 1 - 0.20 = 0.80$$\nThe term $P(T^+ | D^c)$ is the probability of a positive test result given that the patient does not have the disease. This is the false positive rate. It is the complement of the specificity, $P(T^- | D^c)$, since for a patient without the disease, the test can only be positive or negative.\n$$P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - 0.98 = 0.02$$\n\nNow we substitute the expanded expressions for the numerator and the denominator back into our original formula for $P(D | T^+)$.\n$$P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)}$$\nThis is the final derived expression for the post-test probability, which is a form of Bayes' theorem. This expression is also known as the Positive Predictive Value (PPV) of the test.\n\nWe can now substitute the numerical values into this expression:\n$$P(D | T^+) = \\frac{(0.90)(0.20)}{(0.90)(0.20) + (0.02)(0.80)}$$\nFirst, we calculate the numerator and the individual terms in the denominator:\nNumerator: $0.90 \\times 0.20 = 0.18$\nDenominator, first term: $0.90 \\times 0.20 = 0.18$\nDenominator, second term: $0.02 \\times 0.80 = 0.016$\nSo, the expression becomes:\n$$P(D | T^+) = \\frac{0.18}{0.18 + 0.016} = \\frac{0.18}{0.196}$$\nNow, we perform the final division:\n$$P(D | T^+) = \\frac{0.18}{0.196} \\approx 0.9183673469...$$\nThe problem requires the answer to be rounded to four significant figures.\n$$P(D | T^+) \\approx 0.9184$$\n\nFor the clinical interpretation: The initial clinical suspicion (pretest probability) placed the patient's likelihood of having sporotrichosis at $20\\%$. After receiving a positive result from a highly specific PCR assay, the revised probability (post-test probability) has risen dramatically to approximately $92\\%$. A post-test probability of this magnitude is very high and strongly supports the diagnosis. In a clinical setting, this result would provide a high degree of confidence for the clinician to confirm sporotrichosis and initiate appropriate antifungal therapy, likely without the need for more invasive or time-consuming diagnostic procedures like tissue culture, which might otherwise be considered. The high specificity of the test ($98\\%$) means that false positives are rare, reinforcing the confidence in a positive result.", "answer": "$$\n\\boxed{0.9184}\n$$", "id": "4492682"}, {"introduction": "Once a diagnosis is established, designing an effective and safe drug regimen is paramount. This problem applies fundamental pharmacokinetic principles to calculate an appropriate loading and maintenance dose of itraconazole, the standard therapy for sporotrichosis [@problem_id:4492726]. Working through this scenario will build your skills in using key parameters like clearance ($CL$) and volume of distribution ($V_{d}$) to achieve therapeutic drug concentrations efficiently.", "problem": "A $70$ kg adult with lymphocutaneous sporotrichosis is initiated on itraconazole capsules. Assume a one-compartment, linear pharmacokinetic model with first-order elimination and that the following are known and applicable to itraconazole capsules under fed conditions: the apparent volume of distribution over bioavailability, denoted $(V_{d}/F)$, is $10\\,\\text{L/kg}$, and the apparent clearance over bioavailability, denoted $(CL/F)$, is $12\\,\\text{L/h}$. The dosing interval will be $\\tau = 24\\,\\text{h}$. The therapeutic target is an average steady-state plasma concentration $C_{\\text{ss,avg}} = 1\\,\\text{mg/L}$. Capsules are available in $100\\,\\text{mg}$ increments.\n\nUsing only the fundamental definitions of one-compartment linear pharmacokinetics (in particular, that the elimination rate constant is $k = (CL/F)/(V_{d}/F)$, the half-life is $t_{1/2} = \\ln(2)/k$, the average steady-state concentration under repeated dosing satisfies $C_{\\text{ss,avg}} = \\frac{(D/\\tau)}{(CL/F)}$ for dose $D$ given every $\\tau$, and the fraction of steady state achieved by time $t$ is $1 - \\exp(-k t)$), do the following:\n\n1) Derive the daily maintenance dose $D_{\\text{maint}}$ in $\\text{mg/day}$ that achieves $C_{\\text{ss,avg}}$, and round it to the nearest $100\\,\\text{mg}$ to match capsule strength, noting both the unrounded and rounded values.\n\n2) Derive an ideal oral loading dose $D_{\\text{load}}$ in $\\text{mg}$ that instantaneously achieves the target $C_{\\text{ss,avg}}$ at time $t=0$ in this model, and propose a division of $D_{\\text{load}}$ into two doses within the first $24$ hours consistent with $100\\,\\text{mg}$ capsule increments.\n\n3) Compute the elimination half-life $t_{1/2}$ in $\\text{hours}$ from the given parameters.\n\n4) Using the model’s approach to steady state, compute the time $t_{0.9}$ in $\\text{hours}$ to reach $0.9$ of steady state without a loading dose. Then, assuming an ideal loading dose is administered at $t=0$ that places the system on its steady-state concentration trajectory immediately, compute the time to reach $0.9$ of steady state with loading.\n\nFinally, report only the time saved by using the loading dose, defined as the difference in hours between the time to reach $0.9$ of steady state without loading and with loading. Express the final reported time in hours and round your answer to three significant figures.", "solution": "The problem statement is first validated to ensure it is scientifically sound, well-posed, and objective.\n\n**Step 1: Extract Givens**\nThe following data and definitions are provided in the problem statement:\n- Patient weight: $W = 70\\,\\text{kg}$\n- Apparent volume of distribution over bioavailability per kilogram: $(V_{d}/F)_{\\text{per kg}} = 10\\,\\text{L/kg}$\n- Apparent clearance over bioavailability: $(CL/F) = 12\\,\\text{L/h}$\n- Dosing interval: $\\tau = 24\\,\\text{h}$\n- Target average steady-state plasma concentration: $C_{\\text{ss,avg}} = 1\\,\\text{mg/L}$\n- Capsule strength is in increments of $100\\,\\text{mg}$.\n- The model is a one-compartment, linear pharmacokinetic model with first-order elimination.\n- The provided fundamental definitions are:\n  - Elimination rate constant: $k = (CL/F)/(V_{d}/F)$\n  - Half-life: $t_{1/2} = \\ln(2)/k$\n  - Average steady-state concentration: $C_{\\text{ss,avg}} = \\frac{(D/\\tau)}{(CL/F)}$\n  - Fraction of steady state achieved by time $t$: $1 - \\exp(-k t)$\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded (Critical)**: The problem is based on the standard one-compartment model, a cornerstone of pharmacokinetics. The use of itraconazole for lymphocutaneous sporotrichosis is a recognized medical therapy. The pharmacokinetic values provided are reasonable for itraconazole. The problem is scientifically sound.\n- **Well-Posed**: The problem is well-posed. It supplies all necessary parameters and equations to calculate the requested values. Each sub-question has a clear, unique solution derivable from the premises.\n- **Objective (Critical)**: The problem is stated using clear, precise, and unbiased language, employing standard-accepted terminology and definitions from the field of pharmacokinetics.\n- The problem is self-contained and consistent, with no missing information or contradictory constraints. It is not ill-posed, trivial, or reliant on pseudoscience.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A complete solution will be provided.\n\nThe solution proceeds by addressing each part of the problem in sequence. First, we must calculate the total apparent volume of distribution over bioavailability, $(V_d/F)_{\\text{total}}$, for the patient. The clearance, $(CL/F)$, is given as a total value and does not need to be scaled by weight.\nThe total apparent volume of distribution is:\n$$ (V_d/F)_{\\text{total}} = (V_d/F)_{\\text{per kg}} \\times W = (10\\,\\text{L/kg}) \\times (70\\,\\text{kg}) = 700\\,\\text{L} $$\n\n1) **Derivation of the daily maintenance dose, $D_{\\text{maint}}$**\nThe maintenance dose is determined using the given formula for the average steady-state concentration, $C_{\\text{ss,avg}}$.\n$$ C_{\\text{ss,avg}} = \\frac{D_{\\text{maint}}/\\tau}{(CL/F)} $$\nWe solve for the daily maintenance dose, $D_{\\text{maint}}$:\n$$ D_{\\text{maint}} = C_{\\text{ss,avg}} \\times (CL/F) \\times \\tau $$\nSubstituting the given values:\n$$ D_{\\text{maint}} = (1\\,\\text{mg/L}) \\times (12\\,\\text{L/h}) \\times (24\\,\\text{h}) = 288\\,\\text{mg} $$\nThis is the unrounded daily maintenance dose required to achieve the target average steady-state concentration. The problem states that capsules are available in $100\\,\\text{mg}$ increments. Rounding $288\\,\\text{mg}$ to the nearest $100\\,\\text{mg}$ gives a practical daily dose of $300\\,\\text{mg}$.\n\n2) **Derivation of the ideal oral loading dose, $D_{\\text{load}}$**\nAn ideal loading dose, $D_{\\text{load}}$, is designed to instantaneously achieve a target plasma concentration at time $t=0$. In a one-compartment model, the initial concentration $C_0$ is related to the dose $D$ by $C_0 = D \\times F / V_d$. Therefore, the dose required to achieve a target concentration $C_{\\text{target}}$ is $D = C_{\\text{target}} \\times V_d/F$. For the loading dose, the target concentration is the desired average steady-state concentration, $C_{\\text{ss,avg}}$.\n$$ D_{\\text{load}} = C_{\\text{ss,avg}} \\times (V_d/F)_{\\text{total}} $$\nSubstituting the values:\n$$ D_{\\text{load}} = (1\\,\\text{mg/L}) \\times (700\\,\\text{L}) = 700\\,\\text{mg} $$\nThis is the ideal loading dose. Since this is already a multiple of $100\\,\\text{mg}$, it is clinically achievable. A proposed division into two doses within the first $24$ hours could be, for example, $400\\,\\text{mg}$ administered at $t=0$ and $300\\,\\text{mg}$ administered $12$ hours later.\n\n3) **Computation of the elimination half-life, $t_{1/2}$**\nFirst, we compute the elimination rate constant, $k$, using the provided formula and the total pharmacokinetic parameters:\n$$ k = \\frac{(CL/F)}{(V_d/F)_{\\text{total}}} = \\frac{12\\,\\text{L/h}}{700\\,\\text{L}} = \\frac{12}{700}\\,\\text{h}^{-1} = \\frac{3}{175}\\,\\text{h}^{-1} $$\nNow, we compute the half-life, $t_{1/2}$:\n$$ t_{1/2} = \\frac{\\ln(2)}{k} = \\frac{\\ln(2)}{3/175}\\,\\text{h} = \\frac{175\\ln(2)}{3}\\,\\text{h} $$\nCalculation gives $t_{1/2} \\approx 40.43\\,\\text{h}$.\n\n4) **Computation of the time saved by using a loading dose**\nFirst, we find the time to reach $0.9$ (or $90\\%$) of steady state without a loading dose, denoted $t_{0.9}$. We use the given formula for the fraction of steady state, $f(t) = 1 - \\exp(-kt)$.\nLet $f(t_{0.9}) = 0.9$:\n$$ 0.9 = 1 - \\exp(-kt_{0.9}) $$\n$$ \\exp(-kt_{0.9}) = 1 - 0.9 = 0.1 $$\nTaking the natural logarithm of both sides:\n$$ -kt_{0.9} = \\ln(0.1) = -\\ln(10) $$\n$$ t_{0.9} = \\frac{\\ln(10)}{k} $$\nSubstituting the value of $k$:\n$$ t_{0.9} = \\frac{\\ln(10)}{3/175}\\,\\text{h} = \\frac{175\\ln(10)}{3}\\,\\text{h} $$\nNext, we consider the case with an ideal loading dose. The problem states that this dose \"places the system on its steady-state concentration trajectory immediately\". This is an idealization meaning the system behaves as if it is at steady state from $t=0$. Therefore, any fraction of steady state, including $0.9$, is achieved at $t=0$. The time to reach $0.9$ of steady state with a loading dose is $t_{0.9, \\text{load}} = 0\\,\\text{h}$.\n\nThe time saved by using the loading dose is the difference between the time to reach $0.9$ of steady state without the loading dose and with the loading dose.\n$$ \\text{Time saved} = t_{0.9} - t_{0.9, \\text{load}} = \\frac{175\\ln(10)}{3}\\,\\text{h} - 0\\,\\text{h} = \\frac{175\\ln(10)}{3}\\,\\text{h} $$\nTo provide the final answer, we compute the numerical value and round to three significant figures as requested.\n$$ \\text{Time saved} \\approx \\frac{175 \\times 2.302585}{3}\\,\\text{h} \\approx \\frac{402.9524}{3}\\,\\text{h} \\approx 134.3175\\,\\text{h} $$\nRounding to three significant figures, the time saved is $134\\,\\text{h}$.", "answer": "$$\n\\boxed{134}\n$$", "id": "4492726"}, {"introduction": "Patient management extends far beyond initial diagnosis and prescription; it requires continuous monitoring and dynamic adjustment. This problem presents a realistic clinical vignette where you must interpret therapeutic drug monitoring (TDM) and safety laboratory data over time [@problem_id:4492689]. By applying predefined efficacy and toxicity thresholds, you will practice the critical skill of adapting a treatment plan to optimize outcomes while ensuring patient safety.", "problem": "A $54$-year-old immunocompetent horticulturist with lymphocutaneous sporotrichosis confirmed by culture of Sporothrix schenckii sensu lato begins oral itraconazole at $200$ mg/day with food. Therapeutic Drug Monitoring (TDM) is planned to guide dosing to achieve efficacy while minimizing hepatic toxicity. The following fundamental bases apply and are to be used for decision-making in this scenario:\n\n- The trough concentration, denoted $C_{\\text{trough}}$, is the plasma drug level measured immediately before the next dose at steady state, and is used to assess maintenance exposure relative to the therapeutic window.\n- Across the dose range $100$–$400$ mg/day for itraconazole, assume approximate linear pharmacokinetics such that, to a first approximation, $C_{\\text{trough}}$ scales proportionally with the total daily dose.\n- The therapeutic window for cutaneous and lymphocutaneous sporotrichosis is defined here as $C_{\\text{trough}}$ in the range $0.5$–$1.0$ mg/L; values below $0.5$ mg/L are associated with reduced efficacy, and sustained values above $1.0$ mg/L increase the risk of adverse effects without improving outcomes for uncomplicated disease.\n- Hepatotoxicity thresholds follow accepted safety principles: if Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) exceed $3 \\times$ the Upper Limit of Normal (ULN) without hepatic symptoms, dose reduction or temporary holding of therapy is advised; if they exceed $5 \\times$ ULN or if clinical hepatic symptoms (e.g., jaundice, right upper quadrant pain) occur, itraconazole should be discontinued. The ULN for both ALT and AST in this laboratory is $40$ U/L.\n- Alternative therapy for cutaneous sporotrichosis, when azoles are contraindicated due to hepatotoxicity, includes Saturated Solution of Potassium Iodide (SSKI), titrated to clinical response.\n\nBaseline laboratory values prior to initiation are ALT $= 28$ U/L and AST $= 32$ U/L. The patient is asymptomatic from a hepatic standpoint throughout the period described (no jaundice, pruritus, dark urine, abdominal pain). At week $2$, measured $C_{\\text{trough}} = 0.35$ mg/L, ALT $= 92$ U/L, and AST $= 80$ U/L. At week $6$, measured $C_{\\text{trough}} = 1.4$ mg/L, ALT $= 210$ U/L, and AST $= 160$ U/L.\n\nWhich of the following adjustment plans best applies the predefined therapeutic and safety thresholds to optimize efficacy and minimize hepatotoxicity?\n\nA. Week $2$: increase itraconazole to $200$ mg twice daily; Week $6$: reduce to $200$ mg once daily and continue with close monitoring.\n\nB. Week $2$: maintain itraconazole at $200$ mg once daily; Week $6$: continue unchanged to avoid destabilizing therapy.\n\nC. Week $2$: increase itraconazole to $200$ mg twice daily; Week $6$: discontinue itraconazole and switch to Saturated Solution of Potassium Iodide (SSKI) due to transaminase elevations.\n\nD. Week $2$: increase itraconazole to $300$ mg once daily; Week $6$: continue itraconazole and add a hepatoprotective supplement to mitigate enzyme elevations.\n\nE. Week $2$: discontinue itraconazole immediately due to ALT elevation; Week $6$: restart itraconazole at a lower dose after enzymes improve.", "solution": "The decision-making must begin from core definitions of therapeutic windows, trough concentration, and hepatotoxicity thresholds, then apply proportional exposure assumptions to predict and interpret changes.\n\nFirst principles and baseline interpretation:\n\n- The therapeutic window is defined as $C_{\\text{trough}} \\in [0.5, 1.0]$ mg/L for this indication. Efficacy is reduced for $C_{\\text{trough}}  0.5$ mg/L.\n- The hepatotoxicity thresholds use multiples of ULN ($40$ U/L). Specifically:\n  - Action threshold for dose reduction or holding: ALT or AST $ 3 \\times \\text{ULN} = 3 \\times 40 = 120$ U/L without symptoms.\n  - Discontinuation threshold: ALT or AST $ 5 \\times \\text{ULN} = 5 \\times 40 = 200$ U/L, or any hepatic symptoms.\n- Approximate linear pharmacokinetics implies that if dose increases from $D_1$ to $D_2$, then $C_{\\text{trough}}$ scales approximately as $C_2 \\approx C_1 \\times \\frac{D_2}{D_1}$ within the $100$–$400$ mg/day range.\n\nWeek $2$ assessment:\n\n- $C_{\\text{trough}} = 0.35$ mg/L, which is below the target $0.5$ mg/L. From the efficacy standpoint, the base principle indicates a need to increase exposure.\n- ALT $= 92$ U/L and AST $= 80$ U/L. Relative to ULN:\n  - ALT multiple $= \\frac{92}{40} = 2.3 \\times \\text{ULN}  3 \\times \\text{ULN}$.\n  - AST multiple $= \\frac{80}{40} = 2.0 \\times \\text{ULN}  3 \\times \\text{ULN}$.\n- Therefore, hepatotoxicity thresholds do not preclude dose escalation at week $2$; the values are elevated but below $3 \\times \\text{ULN}$, and the patient is asymptomatic. Using the proportionality assumption, increasing dose from $200$ mg/day to $400$ mg/day (i.e., $200$ mg twice daily) would be expected to raise $C_{\\text{trough}}$ from $0.35$ mg/L to approximately $0.35 \\times \\frac{400}{200} = 0.7$ mg/L, which sits within the target window.\n\nWeek $6$ assessment:\n\n- $C_{\\text{trough}} = 1.4$ mg/L, which exceeds the upper bound of the defined therapeutic window ($1.0$ mg/L) for uncomplicated sporotrichosis, increasing risk of adverse effects without proven added benefit.\n- ALT $= 210$ U/L and AST $= 160$ U/L. Relative to ULN:\n  - ALT multiple $= \\frac{210}{40} = 5.25 \\times \\text{ULN}  5 \\times \\text{ULN}$.\n  - AST multiple $= \\frac{160}{40} = 4.0 \\times \\text{ULN}  3 \\times \\text{ULN}$.\n- According to the predefined thresholds, ALT exceeding $5 \\times \\text{ULN}$, even in the absence of hepatic symptoms, mandates discontinuation of itraconazole to minimize hepatotoxicity. In addition, the $C_{\\text{trough}}$ is above the desired range, further supporting a de-escalation rather than continuation. Alternative therapy, specifically Saturated Solution of Potassium Iodide (SSKI), is acceptable for lymphocutaneous sporotrichosis when azoles are contraindicated due to hepatotoxicity.\n\nOption-by-option analysis:\n\nA. Week $2$ increase to $200$ mg twice daily; Week $6$ reduce to $200$ mg once daily and continue with close monitoring.\n- Week $2$ action aligns with efficacy needs and thresholds: increasing to $400$ mg/day is appropriate.\n- Week $6$ action is inappropriate because ALT $= 210$ U/L exceeds $5 \\times \\text{ULN}$. The threshold mandates discontinuation, not mere dose reduction and continuation. Verdict: Incorrect.\n\nB. Week $2$ maintain $200$ mg once daily; Week $6$ continue unchanged.\n- Week $2$ action fails to correct subtherapeutic $C_{\\text{trough}} = 0.35$ mg/L, contrary to the therapeutic window principle.\n- Week $6$ continuation ignores ALT $ 5 \\times \\text{ULN}$. Verdict: Incorrect.\n\nC. Week $2$ increase to $200$ mg twice daily; Week $6$ discontinue itraconazole and switch to SSKI due to transaminase elevations.\n- Week $2$ action appropriately targets $C_{\\text{trough}}$ into the window while remaining within safety limits.\n- Week $6$ action correctly applies the discontinuation threshold ($ 5 \\times \\text{ULN}$) and employs a validated alternative for sporotrichosis. Verdict: Correct.\n\nD. Week $2$ increase to $300$ mg once daily; Week $6$ continue itraconazole and add a hepatoprotective supplement.\n- Week $2$ increasing to $300$ mg/day is a conceivable approach, predicting $C_{\\text{trough}} \\approx 0.35 \\times \\frac{300}{200} = 0.525$ mg/L, barely within target; however, it is less standard than splitting doses, and itraconazole absorption is improved with divided dosing and food. More critically, Week $6$ action disregards the discontinuation threshold ($ 5 \\times \\text{ULN}$), and adding a supplement does not substitute for evidence-based safety actions. Verdict: Incorrect.\n\nE. Week $2$ discontinue itraconazole immediately due to ALT elevation; Week $6$ restart at a lower dose after enzymes improve.\n- Week $2$ action is overly conservative and contradicts thresholds because ALT $= 92$ U/L is $ 3 \\times \\text{ULN}$; dose escalation is indicated for efficacy and remains safe.\n- Week $6$ restart at lower dose ignores the immediate need to discontinue upon lab detection and does not specify an alternative therapy necessary to maintain antifungal treatment during the interruption. Verdict: Incorrect.\n\nTherefore, only option C applies the predefined thresholds accurately at both decision points to optimize efficacy and minimize hepatotoxicity.", "answer": "$$\\boxed{C}$$", "id": "4492689"}]}